Published in J Clin Invest on February 24, 2014
Autophagy in malignant transformation and cancer progression. EMBO J (2015) 2.67
The role for autophagy in cancer. J Clin Invest (2015) 2.11
UPR, autophagy, and mitochondria crosstalk underlies the ER stress response. Trends Biochem Sci (2015) 1.34
Emerging strategies to effectively target autophagy in cancer. Oncogene (2015) 1.26
Cellular and metabolic functions for autophagy in cancer cells. Trends Cell Biol (2014) 1.16
Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors. Cancer Discov (2014) 1.14
Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma. Cell Death Differ (2014) 1.05
Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma. Cancer Discov (2015) 1.02
Phenotype switching in melanoma: implications for progression and therapy. Front Oncol (2015) 1.00
ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma. Mol Syst Biol (2014) 0.97
Autophagy, Metabolism, and Cancer. Clin Cancer Res (2015) 0.95
Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers. Cancer Discov (2014) 0.94
Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells. Oncotarget (2014) 0.94
You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia. Leukemia (2014) 0.93
Chloroquine and hydroxychloroquine for cancer therapy. Mol Cell Oncol (2014) 0.88
Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res (2014) 0.87
Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Ann Surg Oncol (2015) 0.87
Recent insights into the function of autophagy in cancer. Genes Dev (2016) 0.86
Calcium homeostasis and ER stress in control of autophagy in cancer cells. Biomed Res Int (2015) 0.85
Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent. Ecancermedicalscience (2015) 0.85
Interplay between unfolded protein response and autophagy promotes tumor drug resistance. Oncol Lett (2015) 0.82
Cell intrinsic and extrinsic activators of the unfolded protein response in cancer: Mechanisms and targets for therapy. Semin Cancer Biol (2015) 0.82
PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development. J Cell Physiol (2016) 0.82
Development of Novel Immunotherapies for Multiple Myeloma. Int J Mol Sci (2016) 0.82
Maternal obesity alters endoplasmic reticulum homeostasis in offspring pancreas. J Physiol Biochem (2016) 0.80
Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatment. World J Exp Med (2015) 0.80
Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells. Cell Death Dis (2014) 0.80
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas. Oncotarget (2016) 0.80
HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Res (2016) 0.79
GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6. Haematologica (2015) 0.79
Type I interferons mediate pancreatic toxicities of PERK inhibition. Proc Natl Acad Sci U S A (2015) 0.79
Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma. Cell Death Dis (2014) 0.79
Therapeutic Targeting of Autophagy. EBioMedicine (2016) 0.79
Targeting the hallmarks of cancer with therapy-induced endoplasmic reticulum (ER) stress. Mol Cell Oncol (2014) 0.78
Change or die: targeting adaptive signaling to kinase inhibition in cancer cells. Biochem Pharmacol (2014) 0.78
Melanoma and the Unfolded Protein Response. Cancers (Basel) (2016) 0.78
BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma. Oncotarget (2016) 0.78
Inhibition of Autophagy Potentiated the Antitumor Effect of Nedaplatin in Cisplatin-Resistant Nasopharyngeal Carcinoma Cells. PLoS One (2015) 0.78
Variants in autophagy-related genes and clinical characteristics in melanoma: a population-based study. Cancer Med (2016) 0.77
Activation of hERG3 channel stimulates autophagy and promotes cellular senescence in melanoma. Oncotarget (2016) 0.77
AMPK promotes tolerance to Ras pathway inhibition by activating autophagy. Oncogene (2016) 0.77
Amblyomin-X induces ER stress, mitochondrial dysfunction, and caspase activation in human melanoma and pancreatic tumor cell. Mol Cell Biochem (2016) 0.77
Endoplasmic Reticulum Stress, Unfolded Protein Response, and Cancer Cell Fate. Front Oncol (2017) 0.77
BRAF(V600E) inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells. Sci Rep (2016) 0.76
Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors. Oncotarget (2016) 0.76
Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells. Oncotarget (2016) 0.76
Targeting Autophagy in BRAF-Mutant Tumors. Cancer Discov (2015) 0.76
Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer. Proteomes (2016) 0.75
Autophagy- An emerging target for melanoma therapy. F1000Res (2016) 0.75
Mechanism of melanoma cells selective apoptosis induced by a photoactive NADPH analogue. Oncotarget (2016) 0.75
Lead toxicity induces autophagy to protect against cell death through mTORC1 pathway in cardiofibroblasts. Biosci Rep (2015) 0.75
IRE1α-XBP1 pathway promotes melanoma progression by regulating IL-6/STAT3 signaling. J Transl Med (2017) 0.75
Therapeutic interventions to disrupt the protein synthetic machinery in melanoma. Pigment Cell Melanoma Res (2015) 0.75
4th international conference on tumor progression and therapeutic resistance: meeting report. Cancer Biol Ther (2015) 0.75
Novel prosurvival function of Yip1A in human cervical cancer cells: constitutive activation of the IRE1 and PERK pathways of the unfolded protein response. Cell Death Dis (2017) 0.75
Non-cell-autonomous Effects of Autophagy Inhibition in Tumor Cells Promote Growth of Drug-resistant Cells. Mol Pharmacol (2016) 0.75
Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib. J Clin Endocrinol Metab (2016) 0.75
Autophagy and multidrug resistance in cancer. Chin J Cancer (2017) 0.75
Fateful music from a talented orchestra with a wicked conductor: Connection between oncogenic BRAF, ER stress, and autophagy in human melanoma. Mol Cell Oncol (2015) 0.75
Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. Elife (2017) 0.75
Dangerous liaisons: flirtations between oncogenic BRAF and GRP78 in drug-resistant melanomas. J Clin Invest (2014) 0.75
Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. Clin Cancer Res (2015) 0.75
Tumorigenic and Immunosuppressive Effects of Endoplasmic Reticulum Stress in Cancer. Cell (2017) 0.75
Adapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in Melanoma. Front Oncol (2016) 0.75
Targeting Tumor Adaption to Chronic Hypoxia: Implications for Drug Resistance, and How It Can Be Overcome. Int J Mol Sci (2017) 0.75
An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF(V600E) inhibitor-resistant metastatic melanoma cells. Autophagy (2017) 0.75
Targeting the unfolded protein response in cancer. Pharmacol Res (2017) 0.75
Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma. Oncotarget (2017) 0.75
BRAF inhibitors amplify the pro-apoptotic activity of MEK inhibitors by inducing ER stress in NRAS-mutant melanoma. Clin Cancer Res (2017) 0.75
Targeting autophagy in cancer. Nat Rev Cancer (2017) 0.75
Clinical Applications of Autophagy Proteins in Cancer: From Potential Targets to Biomarkers. Int J Mol Sci (2017) 0.75
Melanocytic nevi and melanoma: unraveling a complex relationship. Oncogene (2017) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
The unfolded protein response: from stress pathway to homeostatic regulation. Science (2011) 15.71
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods (2006) 12.63
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Clonogenic assay of cells in vitro. Nat Protoc (2006) 11.85
Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol (2000) 11.62
Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science (2010) 11.29
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest (2007) 9.33
ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell (2009) 9.24
Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov (2008) 7.64
JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell (2008) 7.14
Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol (2005) 7.11
LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol (2004) 6.34
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ (2004) 5.49
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
Endoplasmic reticulum stress triggers autophagy. J Biol Chem (2006) 5.05
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell (2009) 3.85
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell (2013) 3.63
Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol Cell Biol (2004) 3.57
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol (2008) 3.36
The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res (2007) 3.35
Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal (2010) 3.35
The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest (2009) 3.01
Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem J (2011) 2.74
ER-phagy: selective autophagy of the endoplasmic reticulum. Autophagy (2007) 2.21
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol (2012) 2.21
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest (2013) 2.11
Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS One (2009) 2.03
Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene (2010) 1.93
ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J Clin Invest (2012) 1.85
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clin Cancer Res (2011) 1.84
Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci U S A (2012) 1.82
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72
Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome. Clin Cancer Res (2011) 1.69
Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res (2012) 1.41
Autophagy: an ER protein quality control process. Autophagy (2006) 1.26
Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res (2011) 1.24
Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal (2013) 1.19
Immunoperoxidase technique modified by counterstain with azure B as a diagnostic aid in evaluating heavily pigmented melanocytic neoplasms. J Cutan Pathol (1991) 1.09
Autophagy in cutaneous malignant melanoma. J Cutan Pathol (2009) 1.07
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature (2005) 14.65
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science (2009) 10.78
Regulation of cellular metabolism by protein lysine acetylation. Science (2010) 10.55
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 7.86
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res (2007) 7.42
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
A promoter-level mammalian expression atlas. Nature (2014) 6.25
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell (2002) 4.37
Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J (2005) 3.79
Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol (2013) 3.76
The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J (2010) 3.76
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet (2009) 3.65
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62
Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol (2003) 3.51
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 3.42
Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science (2006) 3.37
SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab (2008) 3.35
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25
Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1. Nat Cell Biol (2006) 3.14
Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res (2010) 2.90
Axis of evil: molecular mechanisms of cancer metastasis. Oncogene (2003) 2.81
The MAPK pathway in melanoma. Curr Opin Oncol (2008) 2.80
Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. Nature (2002) 2.78
Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev (2012) 2.70
NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer (2011) 2.69
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res (2008) 2.64
Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet (2011) 2.60
Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem (2002) 2.58
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A (2004) 2.55
Complexin clamps asynchronous release by blocking a secondary Ca(2+) sensor via its accessory α helix. Neuron (2010) 2.52
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron (2013) 2.51
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J (2006) 2.41
Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest (2005) 2.38
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38
Life isn't flat: taking cancer biology to the next dimension. In Vitro Cell Dev Biol Anim (2006) 2.32
An atypical melanocytic lesion without genomic abnormalities shows locoregional metastasis. J Cutan Pathol (2012) 2.31
Suppression of conditioning to ambiguous cues by pharmacogenetic inhibition of the dentate gyrus. Nat Neurosci (2007) 2.30
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2012) 2.28
NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2. Gut (2011) 2.26
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol (2011) 2.20
MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res (2011) 2.15
Isolation of a novel population of multipotent adult stem cells from human hair follicles. Am J Pathol (2006) 2.13
Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nat Genet (2011) 2.13
The approach to the patient with a difficult melanocytic lesion. Pathology (2004) 2.12
Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res (2006) 2.12
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest (2013) 2.11
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res (2009) 2.08
The intra-S phase checkpoint targets Dna2 to prevent stalled replication forks from reversing. Cell (2012) 2.07
Association of high-risk human papillomavirus infection with oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol (2013) 2.07
Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell (2007) 2.03
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol (2012) 2.02
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res (2010) 2.02
The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci (2005) 2.00
Expression of midkine and endoglin in breast carcinomas with different immunohistochemical profiles. APMIS (2010) 2.00
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res (2008) 1.99
Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex. Proc Natl Acad Sci U S A (2003) 1.99
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res (2012) 1.94
The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biol Ther (2006) 1.94
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res (2012) 1.92
Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. Science (2015) 1.91
Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol (2004) 1.90
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res (2012) 1.90
Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem (2003) 1.89
Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr Pathol (2007) 1.89
RIM proteins activate vesicle priming by reversing autoinhibitory homodimerization of Munc13. Neuron (2011) 1.89
Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol (2005) 1.88
Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol (2013) 1.88
Reverse and conventional chemical ecology approaches for the development of oviposition attractants for Culex mosquitoes. PLoS One (2008) 1.87